Important note: Information in this article was accurate in 2005. The state of the art may have changed since the publication date.
|
|
United Press International - October 31, 2005
Both firms said they have granted to the International Partnership for Microbicides royalty-free deals to develop, produce and distribute its compound for use as microbicides in poor countries ravaged by the disease.
The novel compounds subject to the agreements belong to a class of anti-retrovirals known as entry inhibitors that interfere with the ability of the human immunodeficiency virus to attack the host cell. The drugs work by binding either to the virus itself or to its CCR5 receptor.
The licensing pacts mark the first time drug sponsors have licensed an anti-HIV compound as a microbicide at such an early stage in development, the companies said.
051031
UP051015
Copyright © 2005 - United Press International. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through United Press International, Permissions Desk, 1510 H St. N.W. Washington DC 2005. Main Phone Switchboard: 202-898-8000 FAX: 202-898-8057 or 202-898-8147 Email: info@upi.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation UK, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .